Medimmune Ventures, Inc. - Net Worth and Insider Trading
Medimmune Ventures, Inc. Net Worth
The estimated net worth of Medimmune Ventures, Inc. is at least $12 Million dollars as of 2024-04-28. Medimmune Ventures, Inc. is the 10% Owner of G1 Therapeutics Inc and owns about 2,950,630 shares of G1 Therapeutics Inc (GTHX) stock worth over $12 Million. Medimmune Ventures, Inc. is also the 10% Owner of Astria Therapeutics Inc and owns about 27,211 shares of Astria Therapeutics Inc (ATXS) stock worth over $244,899. Details can be seen in Medimmune Ventures, Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Medimmune Ventures, Inc. has not made any transactions after 2017-12-15 and currently still holds the listed stock(s).
Transaction Summary of Medimmune Ventures, Inc.
Medimmune Ventures, Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Medimmune Ventures, Inc. owns 4 companies in total, including G1 Therapeutics Inc (GTHX) , Astria Therapeutics Inc (ATXS) , and Rocket Pharmaceuticals Inc (RCKT) among others .
Click here to see the complete history of Medimmune Ventures, Inc.’s form 4 insider trades.
Insider Ownership Summary of Medimmune Ventures, Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| GTHX | G1 Therapeutics Inc | 2017-12-15 | 10 percent owner |
| ATXS | Astria Therapeutics Inc | 2015-06-30 | 10 percent owner |
| RCKT | Rocket Pharmaceuticals Inc | 2015-02-17 | 10 percent owner |
| AGTC | Applied Genetic Technologies Corp | 2014-03-26 | 10 percent owner |
Medimmune Ventures, Inc. Latest Holdings Summary
Medimmune Ventures, Inc. currently owns a total of 2 stocks. Among these stocks, Medimmune Ventures, Inc. owns 2,950,630 shares of G1 Therapeutics Inc (GTHX) as of December 15, 2017, with a value of $12 Million and a weighting of 97.96%. Medimmune Ventures, Inc. also owns 27,211 shares of Astria Therapeutics Inc (ATXS) as of June 30, 2015, with a value of $244,899 and a weighting of 2.04%.
Latest Holdings of Medimmune Ventures, Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GTHX | G1 Therapeutics Inc | 2017-12-15 | 2,950,630 | 3.99 | 11,773,014 |
| ATXS | Astria Therapeutics Inc | 2015-06-30 | 27,211 | 9.00 | 244,899 |
Holding Weightings of Medimmune Ventures, Inc.
Medimmune Ventures, Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Medimmune Ventures, Inc. has made a total of 0 transactions in G1 Therapeutics Inc (GTHX) over the past 5 years. The most-recent trade in G1 Therapeutics Inc is the sale of 200,000 shares on December 15, 2017, which brought Medimmune Ventures, Inc. around $4 Million.
According to the SEC Form 4 filings, Medimmune Ventures, Inc. has made a total of 0 transactions in Astria Therapeutics Inc (ATXS) over the past 5 years. The most-recent trade in Astria Therapeutics Inc is the acquisition of 3,724 shares on June 30, 2015, which cost Medimmune Ventures, Inc. around $3 Million.
Insider Trading History of Medimmune Ventures, Inc.
- 1
Medimmune Ventures, Inc. Trading Performance
GuruFocus tracks the stock performance after each of Medimmune Ventures, Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Medimmune Ventures, Inc. is -8.82%. GuruFocus also compares Medimmune Ventures, Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Medimmune Ventures, Inc. within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Medimmune Ventures, Inc.'s insider trading performs compared to the benchmark.
Performance of Medimmune Ventures, Inc.
Average Return
116.87%
Outperforming Transactions
67%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.44 | -8.82 | 8.67 | 116.87 | -9.52 | -17.23 |
| Relative Return to S&P 500(%) | 9.06 | -8.35 | 2.71 | 106.56 | -18.76 | -25.1 |
Medimmune Ventures, Inc. Ownership Network
Ownership Network List of Medimmune Ventures, Inc.
Ownership Network Relation of Medimmune Ventures, Inc.
Medimmune Ventures, Inc. Owned Company Details
What does G1 Therapeutics Inc do?
Who are the key executives at G1 Therapeutics Inc?
Medimmune Ventures, Inc. is the 10 percent owner of G1 Therapeutics Inc. Other key executives at G1 Therapeutics Inc include Chief Financial Officer John V. Umstead , Chief Medical Officer Rajesh Malik , and Chief Business Officer Mark Avagliano .
G1 Therapeutics Inc (GTHX) Insider Trades Summary
Over the past 18 months, Medimmune Ventures, Inc. made no insider transaction in G1 Therapeutics Inc (GTHX). Other recent insider transactions involving G1 Therapeutics Inc (GTHX) include a net sale of 69,908 shares made by Rajesh Malik , a net sale of 85,014 shares made by Bailey John E. (jack) Jr. , and a net sale of 7,469 shares made by Terry L Murdock .
In summary, during the past 3 months, insiders sold 35,147 shares of G1 Therapeutics Inc (GTHX) in total and bought 0 shares, with a net sale of 35,147 shares. During the past 18 months, 242,086 shares of G1 Therapeutics Inc (GTHX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 242,086 shares.
G1 Therapeutics Inc (GTHX)'s detailed insider trading history can be found in Insider Trading Tracker table.
G1 Therapeutics Inc Insider Transactions
Medimmune Ventures, Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Medimmune Ventures, Inc.. You might contact Medimmune Ventures, Inc. via mailing address: One Medimmune Way, Gaithersburg Md 20878.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
